NCT04249622 2025-09-16Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast CancerMayo ClinicPhase 2 Terminated20 enrolled 13 charts
NCT06238986 2025-06-25Relationship Between Alterations in the GI Microbiome and GI Inflammation on Symptom Burden in Women With Breast Cancer Receiving ChemotherapyMayo ClinicTerminated9 enrolled